RCT2023 · NEJM · Lincoff AM et al.
SELECT: semaglutide cuts cardiovascular events 20% in non-diabetics
Who, how long
17,604 overweight adults with cardiovascular disease, no diabetes, 3.3 years
What they found
Weekly 2.4 mg semaglutide: –20% major cardiovascular events, –9% body weight; the benefit emerged before the weight loss.
⚠ Caveat
Manufacturer-funded; 16.6% discontinued for side effects; no detailed data on muscle loss.
Related in the knowledge base
Last reviewed: 6 September 2026
This site is educational and does not replace medical advice. Start any supplement or drug only after consulting a doctor or pharmacist.